[1]马 娟,侯彦杰,陈路锋,等.肌肉质量减少对不同部位肿瘤病人的预后分析[J].肠外与肠内营养杂志,2024,(05):293-299.[doi:DOI : 10.16151/j.1007-810x.2024.05.007]
　MA Juan,HOU Yan-jie,CHEN Lu-feng,et al.Analysis of muscle mass reduction on the prognosis of patients withtumors in different locations[J].PARENTERAL & ENTERAL NUTRITION,2024,(05):293-299.[doi:DOI : 10.16151/j.1007-810x.2024.05.007]
点击复制

肌肉质量减少对不同部位肿瘤病人的预后分析()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2024年05期
页码:
293-299
栏目:
论著
出版日期:
2024-10-10

文章信息/Info

Title:
Analysis of muscle mass reduction on the prognosis of patients withtumors in different locations
作者:
马 娟1; 2; 侯彦杰 2; 陈路锋2; 侯双双1; 2; 李险峰2
1. 山西医科大学第一临床医学院，山西太原 030000；2. 山西医科大学第一医院放疗科，山西太原030000
Author(s):
MA Juan1; 2;  HOU Yan-jie2;  CHEN Lu-feng2;  HOU Shuang-shuang1; 2;  LI Xian-feng2
1. First Clinical Medical College Of Shanxi Medical University, Taiyuan 030000, Shanxi, China；2.Department of Radiotherapy, First Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi,China
关键词:
肿瘤 ; 肌肉质量 ; 预后 ; 总生存率 ; 癌症特异性生存率
Keywords:
Tumor;  Muscle mass;  Prognosis;  Overall survival;  Cancer-specific survival
分类号:
R730.7
DOI:
DOI : 10.16151/j.1007-810x.2024.05.007
文献标志码:
A
摘要:
目的：分析肌肉质量减少对肿瘤病人预后的影响，并观察肌肉质量减少在不同肿瘤病人预后中的差异。 方法：选用 NHANES 数据库中 1999 ~ 2006 年及 2011 ~ 2018 年可获得肌肉质量的肿瘤病人作为研究对象，将其根据 DXA 测量的肌肉质量差异分成肌肉质量减少组和非肌肉质量减少组。通过 Cox 回归多因素分析肌肉质量减少对肿瘤病人预后的影响，并将病人不同肿瘤部位进行亚组分析，分析肌肉质量减少对其总生存率（OS）及癌症特异性生存率（CSS）产生的差异。 结果：本研究共纳入肿瘤病人 1 663 人，其中头颈部肿瘤病人 64 例，皮肤肿瘤病人 478 例，乳腺肿瘤病人 237 例，肺部肿瘤病人 39 例，消化系统肿瘤病人 138 例，泌尿系统肿瘤病人 253 例，妇科肿瘤病人 264 例，血液系统肿瘤病人 64 例，其他部位肿瘤病人 103 例。共分为肌肉质量降低组 517 例，非肌肉质量降低 1 146 例。肌肉质量降低的肿瘤组病人 OS 以及 CSS 显著低于非肌肉质量降低组（OS，HR = 1.358；CSS，HR =2.109）。其中肌肉质量降低与头颈部肿瘤病人的 OS 显著相关（HR = 4.060），在泌尿系统肿瘤病人中，肌肉质量降低组 OS 及 CSS 都明显更差（OS，HR = 1.625；CSS，HR = 2.311），而其余肿瘤病人在未表现出明显差异性。 结论：肌肉质量降低的肿瘤病人较正常肿瘤病人的 OS 以及 CSS 明显更差，且对不同部位的肿瘤病人表现出不同的预后影响性，尤其需关注头颈部肿瘤及泌尿系统肿瘤的肌肉质量状况并及时干预。
Abstract:
Objective: To analyze the impact of muscle mass reduction on the prognosis of patients and to observethe differences in prognosis among patients with different types of tumors affected by muscle mass reduction. Method:Tumor patients with available muscle mass data from the National Health and Nutrition Examination Survey, NHANES(NHANES) database (1999 ~ 2006 and 2011 ~ 2018) were selected as study subjects. Patients were divided into a musclemass reduction group and a non-muscle mass reduction group based on differences measured by Dual-energy X-rayAbsorptiometry (DXA). A Cox regression multivariate analysis was conducted to evaluate the impact of muscle massreduction on the prognosis of tumor patients, and a subgroup analysis was performed based on different tumor locationsto analyze the differences in overall survival (OS) and cancer-specific survival (CSS) associated with muscle massreduction. Result: A total of 1 663 tumor patients were included in the study, comprising 64 with head and neck tumors,478 with skin tumors, 237 with breast tumors, 39 with lung tumors, 138 with digestive system tumors, 253 withurological system tumors, 264 with gynecological tumors, 64 with hematological system tumors, and 103 with tumors inother locations. There were 517 patients in the muscle mass reduction group and 1,146 in the non-muscle mass reductiongroup. Patients in the muscle mass reduction group showed significantly lower OS and CSS compared to the non-muscle mass reduction group (OS, HR = 1.358; CSS, HR = 2.109). Muscle mass reduction was significantly associated with OSin head and neck tumor patients (HR = 4.060) and both OS and CSS were significantly worse in urinary system tumorpatients in the muscle mass reduction group (OS, HR = 1.625; CSS, HR = 2.311), whereas no significant differenceswere observed in other tumors. Conclusion: Tumor patients with muscle mass reduction have significantly worse OSand CSS compared to those with normal muscle mass, and the prognosis varies across different tumor sites. Specialattention should be given to muscle mass status in patients with head and neck tumors and urinary system tumors, withtimely interventions as needed.

参考文献/References:


[1] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:European consensus on definition and diagnosis: report of theEuropean working group on sarcopenia in older people[J]. AgeAgeing, 2010, 39(4): 412-423.
[2] Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletalmuscle strength, mass, and quality in older adults: the health,aging and body composition study[J]. J Gerontol A Biol Sci MedSci, 2006, 61(10): 1059-1064.
[3] Shachar SS, Williams GR, Muss HB, et al. Prognostic value ofsarcopenia in adults with solid tumours: a meta-analysis andsystematic review[J]. Eur J Cancer, 2016, 57: 58-67.
[4] Graves JP, Daher GS, Bauman MMJ, et al. Association ofsarcopenia with oncologic outcomes of primary treatment amongpatients with oral cavity cancer: a systematic review and metaanalysis[J]. Oral Oncol, 2023, 147: 106608.
[5] Salavatizadeh M, Soltanieh S, Radkhah N, et al. The associationbetween skeletal muscle mass index (SMI) and survival aftergastrectomy: a systematic review and meta-analysis of cohortstudies[J]. Eur J Surg Oncol, 2023, 49(11): 106980.
[6] Watanabe A, Oshikiri T, Sawada R, et al. Actual sarcopeniareflects poor prognosis in patients with esophageal cancer[J]. AnnSurg Oncol, 2022, 29(6): 3670-3681.
[7] 董丹妮, 楚 翘, 项 密, 等 . 肺癌病人合并肌少症研究进展[J].肠外与肠内营养, 2024, 31(3): 184-188, 192.
[8] Ballinger TJ, Marques HS, Xue G, et al. Impact of musclemeasures on outcome in patients receiving endocrine therapy formetastatic breast cancer: analysis of ECOG-ACRIN E2112[J]. JNatl Compr Canc Netw, 2023, 21(9): 915-923.e1.
[9] National Center for Health Statistics. National health andnutrition examination survey[EB/OL]. [2023-08-18]. https://www.cdc.gov/nchs/nhanes/index.htm.
[10] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revisedEuropean consensus on definition and diagnosis[J]. Age Ageing,2019, 48(1): 16-31.
[11] Zhang FM, Song CH, Guo ZQ, et al. Sarcopenia prevalence inpatients with cancer and association with adverse prognosis: anationwide survey on common cancers[J]. Nutrition, 2023, 114:112107.
[12] Jogiat UM, Bédard ELR, Sasewich H, et al. Sarcopenia reducesoverall survival in unresectable oesophageal cancer: a systematicreview and meta-analysis[J]. J Cachexia Sarcopenia Muscle,2022, 13(6): 2630-2636.
[13] Williams GR, Dunne RF, Giri S, et al. Sarcopenia in the olderadult with cancer[J]. J Clin Oncol, 2021, 39(19): 2068-2078.
[14] Abe S, Nozawa H, Sasaki K, et al. Sarcopenia is associated withoncological prognosis and the incidence of secondary cancer inpatients with middle/lower rectal cancer[J]. Clin ColorectalCancer, 2023, 22(1): 143-152.
[15] Poisson J, Martinez-Tapia C, Heitz D, et al. Prevalence andprognostic impact of cachexia among older patients with cancer:a nationwide cross-sectional survey (NutriAgeCancer) [J]. JCachexia Sarcopenia Muscle, 2021, 12(6): 1477-1488.
[16] Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Associationof systemic inflammation and sarcopenia with survival innonmetastatic colorectal cancer: results from the C SCANS study[J]. JAMA Oncol, 2017, 3(12): e172319.
[17] Fang PH, Zhou JF, Xiao X, et al. The prognostic value ofsarcopenia in oesophageal cancer: a systematic review and metaanalysis[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 3-16.
[18] Bossi P, Delrio P, Mascheroni A, et al. The spectrum ofmalnutrition/cachexia/sarcopenia in oncology according todifferent cancer types and settings: a narrative review[J].Nutrients, 2021, 13(6): 1980.
[19] Hua X, Liao JF, Huang X, et al. Sarcopenia is associated withhigher toxicity and poor prognosis of nasopharyngeal carcinoma[J]. Ther Adv Med Oncol, 2020, 12: 1758835920947612.
[20] Psutka SP, Carrasco A, Schmit GD, et al. Sarcopenia in patientswith bladder cancer undergoing radical cystectomy: impact oncancer-specific and all-cause mortality[J]. Cancer, 2014, 120(18):2910-2918.
[21] Korczak J, Mardas M, Litwiniuk M, et al. Androgen deprivationtherapy for prostate cancer influences body compositionincreasing risk of sarcopenia[J]. Nutrients, 2023, 15(7): 1631.
[22] Chiang PK, Tsai WK, Chiu AWH, et al. Muscle loss duringandrogen deprivation therapy is associated with higher risk ofnon-cancer mortality in high-risk prostate cancer[J]. Front Oncol,2021, 11:722652.
[23] de Pablos-Rodríguez P, Del Pino-Sede?o T, Infante-Ventura D, etal. Prognostic impact of sarcopenia in patients with advancedprostate carcinoma: a systematic review[J]. J Clin Med, 2022, 12(1): 57.
[24] Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association ofmuscle and adiposity measured by computed tomography withsurvival in patients with nonmetastatic breast cancer[J]. JAMAOncol, 2018, 4(6): 798-804.
[25] Takenaka Y, Oya R, Takemoto N, et al. Predictive impact ofsarcopenia in solid cancers treated with immune checkpointinhibitors: a meta-analysis[J]. J Cachexia Sarcopenia Muscle,2021, 12(5): 1122-1135.
[26] 周 凡, 包金枫, 卢 慧, 等 . 宫颈癌放化疗期间骨骼肌指数的变化及其与预后的相关性研究[J]. 肠外与肠内营养, 2024, 31(4): 211-219.

相似文献/References:

[1]王俊杰,谈善军,吴国豪.肠道菌群在癌性恶病质营养代谢及治疗中的作用[J].肠外与肠内营养杂志,2021,(01):49.[doi:DOI : 10.16151/j.1007-810x.2021.01.011]
　WANG Jun-jie,TAN Shan-jun,WU Guo-hao.The role of gut microbiota in the pathogenesis and treatment of cancer cachexia[J].PARENTERAL & ENTERAL NUTRITION,2021,(05):49.[doi:DOI : 10.16151/j.1007-810x.2021.01.011]
[2]杨谨成,王黎明,李彩云,等.肿瘤医院肝胆外科住院病人营养现状调查及模型预测[J].肠外与肠内营养杂志,2022,(06):321.[doi:10.16151/j.1007-810x.2022.06.001]
　YANG Jin-cheng,WANG Li-ming,LI Cai-yun,et al.Survey of inpatients' nutrition and model prediction in hepatobiliary surgery of cancer hospital[J].PARENTERAL & ENTERAL NUTRITION,2022,(05):321.[doi:10.16151/j.1007-810x.2022.06.001]
[3]邢婷婷,李嘉琪,刘 云,等.维持性血液透析病人捏力及握力与肌肉质量的相关性研究[J].肠外与肠内营养杂志,2023,(06):340.[doi:10.16151/j.1007-810x.2023.06.004]
　XING Ting-ting,LI Jia-qi,LIU Yun,et al.A study of correlation between pinch and grip strength and muscle mass in maintenance hemodialysis patients[J].PARENTERAL & ENTERAL NUTRITION,2023,(05):340.[doi:10.16151/j.1007-810x.2023.06.004]

备注/Memo

备注/Memo:
作者简介 ：马 娟，医学硕士研究生，主要从事肿瘤学相关研究。E-mail：1178887583@qq.com通讯作者 ：李险峰，E-mail：lixianfeng-lxf@263.net
更新日期/Last Update: 1900-01-01